MARKET

VCYT

VCYT

Veracyte
NASDAQ
19.90
+0.07
+0.35%
Closed 16:03 04/24 EDT
OPEN
19.85
PREV CLOSE
19.83
HIGH
20.07
LOW
19.66
VOLUME
511.68K
TURNOVER
0
52 WEEK HIGH
30.52
52 WEEK LOW
18.61
MARKET CAP
1.49B
P/E (TTM)
-19.4298
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VCYT last week (0415-0419)?
Weekly Report · 2d ago
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
A new study shows the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress. The Decipher test is the only gene expression test to have treatment-outcome data from a prospective, phase 2, randomized trial for prostate cancer. Veracyte is a leading cancer diagnostics company. The findings are from the ENACT clinical trial.
Barchart · 3d ago
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha · 6d ago
Veracyte Announces 9 Abstracts Reinforcing The Value Of Decipher Prostate And Decipher Bladder Testing Will Be Presented At AUA 2024
Nine abstracts will be presented at AUA 2024, the annual meeting of the American Urological Association. Studies will evaluate the clinical utility of Veracyte's Decipher tests for patients with prostate or bladder cancer. The company is a leading cancer diagnostics company. The abstracts focus on its Decipher Prostate and Decipher Bladder Genomic Classifiers.
Benzinga · 04/16 12:42
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Nine abstracts will be presented at AUA 2024, the annual meeting of the American Urological Association. Studies will evaluate the clinical utility of Veracyte’s Decipher tests in guiding treatment decisions for patients with prostate or bladder cancer. Other presentations will explore new insights into these cancers’ underlying biology.
Barchart · 04/16 07:30
Weekly Report: what happened at VCYT last week (0408-0412)?
Weekly Report · 04/15 10:06
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 04/14 21:56
Weekly Report: what happened at VCYT last week (0401-0405)?
Weekly Report · 04/08 10:09
More
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Webull offers Veracyte Inc stock information, including NASDAQ: VCYT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCYT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VCYT stock methods without spending real money on the virtual paper trading platform.